Amikacin liposomal inhaled - Insmed

Drug Profile

Amikacin liposomal inhaled - Insmed

Alternative Names: ALIS; Amikacin Liposome Inhalation Suspension; Amikacin sustained release; Arikace; ARIKAYCE; Liposomal amikacin for inhalation; SLIT™ Amikacin

Latest Information Update: 07 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Transave
  • Developer Insmed; National Institute of Allergy and Infectious Diseases; Oregon Health & Science University; University of Texas Health Science Center at Tyler
  • Class Aminoglycosides; Antibacterials; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mycobacterial infections; Cystic fibrosis-associated respiratory tract infections
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Cystic fibrosis-associated respiratory tract infections; Mycobacterial infections
  • Phase II Bronchiectasis

Most Recent Events

  • 05 Sep 2017 Insmed plans to pursue accelerated approval of amikacin liposomal inhaled under subpart H based on the data from the phase III CONVERT study in Mycobacterial infections
  • 05 Sep 2017 Top-line efficacy and adverse events data from the phase III CONVERT trial in Mycobacterial infections released by Insmed
  • 14 Feb 2017 Insmed receives patent covering amikacin liposomal inhalation for Infections (Pulmonary) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top